Polymorphisms of metal transporter genes DMT1 and ATP7A in wilson's disease

Journal of Trace Elements in Medicine and Biology

Volumn 28, Issue 1, 2014, Pages 8-12

  Przybyłkowski, Adam ^a,b   Gromadzka, Grazyna ^a,c   Członkowska, Anna ^c  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Department of Gastroenterology ^*  (Poland)

^c INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

ATP7A; DMT1; Polymorphism; Wilson's disease

Indexed keywords

MENKES PROTEIN; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2;

ADULT; ALLELE; ARTICLE; ATP7A GENE; CONTROLLED STUDY; DMT1 GENE; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WILSON DISEASE;

ATP7A; DMT1; POLYMORPHISM; WILSON'S DISEASE;

ADENOSINE TRIPHOSPHATASES; ADULT; CATION TRANSPORT PROTEINS; COPPER; FEMALE; GENOTYPE; HEPATOLENTICULAR DEGENERATION; HUMANS; MALE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84890891437     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2013.08.002     Document Type: Article

References (37)

1. Ala A., Walker A.P., Ashkan K., Dooley J.S., Schilsky M.L. Wilson's disease. Lancet 2007, 369(9559):397-408.
2. Gromadzka G., Rudnicka M., Chabik G., Przybylkowski A., Czlonkowska A. Genetic variability in the methylenetetrahydrofolate reductase gene (MTHFR) affects clinical expression of Wilson's disease. J Hepatol 2011, 55(4):913-919.
3. Gromadzka G., Schmidt H.H., Genschel J., Bochow B., Rodo M., Tarnacka B., et al. Frameshift and nonsense mutations in the gene for ATPase7B are associated with severe impairment of copper metabolism and with an early clinical manifestation of Wilson's disease. Clin Genet 2005, 68(6):524-532.
4. Gromadzka G., Schmidt H.H., Genschel J., Bochow B., Rodo M., Tarnacka B., et al. p.H1069Q mutation in ATP7B and biochemical parameters of copper metabolism and clinical manifestation of Wilson's disease. Mov Disord 2006, 21(2):245-248.
5. Merle U., Weiss K.H., Eisenbach C., Tuma S., Ferenci P., Stremmel W. Truncating mutations in the Wilson disease gene ATP7B are associated with very low serum ceruloplasmin oxidase activity and an early onset of Wilson disease. BMC Gastroenterol 2010, 10:p8.
6. Stapelbroek J.M., Bollen C.W., van Amstel J.K., van Erpecum K.J., van Hattum J., van den Berg L.H., et al. The H1069Q mutation in ATP7B is associated with late and neurologic presentation in Wilson disease: results of a meta-analysis. J Hepatol 2004, 41(5):758-763.
7. Schiefermeier M., Kollegger H., Madl C., Polli C., Oder W., Kuhn H., et al. The impact of apolipoprotein E genotypes on age at onset of symptoms and phenotypic expression in Wilson's disease. Brain 2000, 123(Pt 3):585-590.
8. Merle U., Stremmel W., Gessner R. Influence of homozygosity for methionine at codon 129 of the human prion gene on the onset of neurological and hepatic symptoms in Wilson disease. Arch Neurol 2006, 63(7):982-985.
9. Litwin T., Gromadzka G., Czlonkowska A. Gender differences in Wilson's disease. J Neurol Sci 2012, 312(1-2):31-35.
10. Litwin T., Gromadzka G., Czlonkowska A., Apolipoprotein E gene (APOE) genotype in Wilson's disease: impact on clinical presentation. Parkinson Relat Disord 2012, 18(4):367-369.
11. Litwin T., Gromadzka G., Czlonkowska A., Golebiowski M., Poniatowska R. The effect of gender on brain MRI pathology in Wilson's disease. Metab Brain Dis 2013, 28(1):69-75.
12. Gromadzka G., Czlonkowska A. Influence of IL-1RN intron 2 variable number of tandem repeats (VNTR) polymorphism on the age at onset of neuropsychiatric symptoms in Wilson's disease. Int J Neurosci 2011, 121(1):8-15.
13. Weiss K.H., Runz H., Noe B., Gotthardt D.N., Merle U., Ferenci P., et al. Genetic analysis of BIRC4/XIAP as a putative modifier gene of Wilson disease. J Inherit Metab Dis 2010, [Epub ahead of print].
14. Shiono Y., Wakusawa S., Hayashi H., Takikawa T., Yano M., Okada T., et al. Iron accumulation in the liver of male patients with Wilson's disease. Am J Gastroenterol 2001, 96(11):3147-3151.
15. Lloyd D.R., Phillips D.H. Oxidative DNA damage mediated by copper(II), iron(II) and nickel(II) fenton reactions: evidence for site-specific mechanisms in the formation of double-strand breaks, 8-hydroxydeoxyguanosine and putative intrastrand cross-links. Mutat Res 1999, 424(1-2):23-36.
16. Sharp P. The molecular basis of copper and iron interactions. Proc Nutr Soc 2004, 63(4):563-569.
17. Mackenzie B., Hediger M.A. SLC11 family of H+-coupled metal-ion transporters NRAMP1 and DMT1. Pflugers Arch 2004, 447(5):571-579.
18. Salazar J., Mena N., Hunot S., Prigent A., Alvarez-Fischer D., Arredondo M., et al. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci USA 2008, 105(47):18578-18583.
19. Johnson S. Is Parkinson's disease the heterozygote form of Wilson's disease: PD=1/2 WD?. Med Hypotheses 2001, 56(2):171-173.
20. Kaler S.G. Menkes disease. Adv Pediatr 1994, 41:263-304.
21. Chen D.B., Feng L., Lin X.P., Zhang W., Li F.R., Liang X.L., et al. Penicillamine increases free copper and enhances oxidative stress in the brain of toxic milk mice. PLoS ONE 2012, 7(5):pe37709.
22. Kim B.E., Turski M.L., Nose Y., Casad M., Rockman H.A., Thiele D.J. Cardiac copper deficiency activates a systemic signaling mechanism that communicates with the copper acquisition and storage organs. Cell Metab 2010, 11(5):353-363.
23. Ravin H.A. An improved colorimetric enzymatic assay of ceruloplasmin. J Lab Clin Med 1961, 58:161-168.
24. Zoller H., Pietrangelo A., Vogel W., Weiss G. Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis. Lancet 1999, 353(9170):2120-2123.
25. Arredondo M., Munoz P., Mura C.V., Nunez M.T. DMT1, a physiologically relevant apical Cu1+ transporter of intestinal cells. Am J Physiol Cell Physiol 2003, 284(6):C1525-C1530.
26. Nose Y., Kim B.E., Thiele D.J. Ctr1 drives intestinal copper absorption and is essential for growth, iron metabolism, and neonatal cardiac function. Cell Metab 2006, 4(3):235-244.
27. Fox P.L. The copper-iron chronicles: the story of an intimate relationship. Biometals 2003, 16(1):9-40.
28. Morita H., Ikeda S., Yamamoto K., Morita S., Yoshida K., Nomoto S., et al. Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann Neurol 1995, 37(5):646-656.
29. Erhardt A., Hoffmann A., Hefter H., Haussinger D. HFE gene mutations and iron metabolism in Wilson's disease. Liver 2002, 22(6):474-478.
30. Walshe J.M., Cox D.W. Effect of treatment of Wilson's disease on natural history of haemochromatosis. Lancet 1998, 352(9122):112-113.
31. Engelbrecht V., Schlaug G., Hefter H., Kahn T., Modder U. MRI of the brain in Wilson disease: T2 signal loss under therapy. J Comput Assist Tomogr 1995, 19(4):635-638.
32. Zheng W., Monnot A.D. Regulation of brain iron and copper homeostasis by brain barrier systems: implication in neurodegenerative diseases. Pharmacol Ther 2012, 133(2):177-188.
33. Wysokinski D., Zaras M., Dorecka M., Waszczyk M., Szaflik J., Blasiak J., et al. An association between environmental factors and the IVS4+44C>A polymorphism of the DMT1 gene in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2012, 250(7):1057-1065.
34. He Q., Du T., Yu X., Xie A., Song N., Kang Q., et al. DMT1 polymorphism and risk of Parkinson's disease. Neurosci Lett 2011, 501(3):128-131.
35. Kelleher T., Ryan E., Barrett S., O'Keane C., Crowe J. DMT1 genetic variability is not responsible for phenotype variability in hereditary hemochromatosis. Blood Cells Mol Dis 2004, 33(1):35-39.
36. Howitt J., Putz U., Lackovic J., Doan A., Dorstyn L., Cheng H., et al. Divalent metal transporter 1 (DMT1) regulation by Ndfip1 prevents metal toxicity in human neurons. Proc Natl Acad Sci USA 2009, 106(36):15489-15494.
37. Ingrassia R., Lanzillotta A., Sarnico I., Benarese M., Blasi F., Borgese L., et al. 1B/(-)IRE DMT1 expression during brain ischemia contributes to cell death mediated by NF-kappaB/RelA acetylation at Lys310. PLoS ONE 2012, 7(5):pe38019.